LONDON--(BUSINESS WIRE)-- At a glimpse, drug discovery can appear to be a straightforward process of screening compound candidates, optimizing leads, performing pre-clinical evaluations and then, with these steps completed, clinical trials can begin. The reality is not so neat. These activities often overlap, merge, and conflict with each other. So ADME (absorption, distribution, metabolism, excretion) and toxicology are not simply a step in lead optimization – they are actually an integral part of an ongoing process.
New market research report “Early Toxicology: Markets and Approaches” worked out by Kalorama Information is aimed at examining present and emerging technologies and techniques, issues, and opportunities related to early toxicology testing in drug discovery. It pinpoints some of the ways that big pharma companies approach detecting toxicity and includes current and projected market analysis for in-silico, in-vitro, and in-vivo early toxicology products. Furthermore, the study is supplemented with elaborate profiles of 30 key suppliers, their products and market approach.
Title: Early Toxicology: Markets and Approaches
Published: September 12, 2012
Price: US$ 3,995.00
More Drugs & Biotechnology Market Studies by Kalorama Information Include:
- Epigenetics: Applications for Pharmaceuticals and Diagnostics (Methylation, Histone Modification and miRNA expression)
- The World Market for Transdermal Drug Delivery
More new research reports by Kalorama Information can be found at http://marketpublishers.com/members/kalorama_info/info.html
Source: The Market Publishers